2Feil R,Lohmann SM,de Jonge H,et al.Cyclic GMP-dependent protein kinases and the cardiovascular system insights from genetically modified mice[J].Circ Res,2003,93(10):907.
3Burger AJ.A review of the renal and neurohormonal effects of B-type natriuretic peptide[J].Congest Heart Fail,2005,11(1):30.
4D'Souza SP,Yellon DM,Martin C,et al.B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening[J].Am J Physiol Heart Circ Physiol,2003,284(5):H1 592.
5Kapoun AM,Liang F,O'Young G,et al.B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts:fibrosis,myofibroblast conversion,proliferation,and inflammation[J].Circ Res,2004,94(4):453.
6Spinale FG.Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases[J].Circ Res,2002,91(12):1 082.
8Young JB,Abraham WT,Stevenson LW,et al.Intraverous nesiritide vs.nitroglycerin for treatment of decompensated congestive heart failure:A randomized antrolled trial[J].The Journal of the American Medical Association,2002,287(12):1 531.
9Marcus LS,Hart D,Packer M,et al.Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure:A double-blind,placebo-controlled,randomized crossover trial[J].Circulation,1996,94(12):3 184.
10Burger AJ,Horton DP,LeJemtel T,et al.Effect of nesiritide(B-type natriuretic peptide)and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure:The PRECEDENT study[J].Am Heart J,2002,144(6):1 102.
二级参考文献11
1Krum H, Liew D. New and emerging drug therapies for the management of acute heart failure[J]. Intern Med J,2003,33:515-520.
2Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial[J]. JAMA, 2002, 287: 1531-1540.
3Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes[J] .Am J Cardiol, 2005,96:11G-17G.
4Azzazy HM, Christenson RH. B-type natriuretic peptide: physiologic role and assay characteristics[J] .Heart Fail Rev,2003,8:315-320.
6Zineh I, Schofield RS, Johnson JA. The evolving role of nesiritide in advanced or decompensated heart failure[J] .pharmacotherapy,2003,23:1266-1280.
7Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology[J]. Eur Heart J,2005,26:384-416.
8Trovate GM,Carpinteri G.Effects of atria1 fibrillation on the increase of atria1 natruretic peptide in congestive heart failure.Recenti Prog Med,1994;85:570
9Muscholl MW,Schunkert H,Muders T,et al.Neurohormone activity and left ventricular geometry in patients with essential arterial hypertension.Am Heart J,1998;135:58
10Nieminen MS,Bohm M,Cowie MR,et al.Executive summary of the guidelines on the diagnos is and treatment of acute heart failure:the task force on acute heart failure of the european society of cardiology[J].Eur Heart J,2005,26(4):384-416.
